Dare Bioscience, Inc. 8-K

What Happened Dare Bioscience, Inc. (DARE) filed an 8-K reporting that on April 16, 2026 Gregory W. Matz voluntarily resigned as a Class II director and the board simultaneously reappointed him as a Class III director to rebalance its three director classes. The board currently has six members; Class III directors (including Matz and Sabrina Martucci Johnson) will stand for re-election at the company's 2026 annual meeting of stockholders. The company filed the report on April 17, 2026.

Key Details

• Board size: 6 directors; board divided into three classes with staggered three-year terms.
• Reclassification: Matz moved from Class II (term previously expiring 2028) to Class III (term expiring at the 2026 annual meeting).
• Effective date: Matz’s resignation and reappointment occurred April 16, 2026; 8-K filed April 17, 2026.
• No change to committee assignments and his service is treated as uninterrupted.

Why It Matters This is a governance change to rebalance board classes ahead of the 2026 shareholder vote; it does not indicate a change in leadership or committee roles. For investors, the immediate impact is limited—expect Matz and Sabrina Martucci Johnson to be on the ballot at the 2026 annual meeting. Monitor the proxy and annual meeting materials for any additional governance or director election disclosures.